Lantheus Holdings, Inc. (LNTH) Stock Analysis
Healthcare · Drug Manufacturers - Specialty & Generic · NasdaqGM
Lantheus Holdings, Inc. (LNTH) posted $1.54B in revenue for fiscal 2025 (up 0.5% year over year), at a 15.2% net margin, and has compounded revenue about 35.3%/yr over five years, per its SEC filings.
Data last refreshed August 2, 2026 from SEC filings · how we compute this
The analyst's take on Lantheus Holdings, Inc.
Lantheus Holdings, Inc. has grown revenue from $301.85M to $1.54B over the last 10 fiscal years, compounding about 35.3% a year. The most recent year was up 0.5%, so growth has cooled from its longer-run pace.
Net margin sits at 15.2%, down 5.2 points year over year on a 61.1% gross margin.
At today's valuation the market is pricing in roughly 6.6% annual free-cash-flow growth — versus the 84.9% it actually delivered over the last five years, so the price is arguably undemanding against what it has already proven.
Synthesised from Lantheus Holdings, Inc.'s SEC filings — descriptive, not advice. Ask the analyst your own question →
Lantheus Holdings, Inc. revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $301.85M | $331.38M | $343.37M | $347.34M | $339.41M | $425.21M | $935.06M | $1.30B | $1.53B | $1.54B |
| Gross profit | $137.78M | $162.13M | $174.88M | $174.81M | $138.76M | $187.69M | $581.70M | $709.54M | $988.29M | $941.95M |
| Net income | $0 | $123.39M | $40.52M | $31.67M | $-13.47M | $-71.28M | $28.07M | $326.66M | $312.44M | $233.56M |
| Net margin | 0.0% | 37.2% | 11.8% | 9.1% | -4.0% | -16.8% | 3.0% | 25.2% | 20.4% | 15.2% |
Source: Lantheus Holdings, Inc. SEC filings (10-K). 13 years of history available in the interactive view.
Lantheus Holdings, Inc.: no obvious red flags in the filings
Our deterministic scan of the filed statements — receivables vs sales, earnings vs cash, dilution, leverage and margins — didn't flag anything. Ask about the risks →
What growth is priced into LNTH stock?
At today's market cap of $6.55B, Lantheus Holdings, Inc. is priced for free-cash-flow growth of about 6.6% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $354.05M from the FY ending 2025-12-31). For comparison, free cash flow actually grew 84.9%/yr over the last five fiscal years and revenue 35.3%/yr, computed from its SEC filings. This is a reverse DCF — a translation of the price into a growth assumption you can judge, not a fair value and not advice. Change the assumptions yourself in the interactive view →
Explore 13 years of Lantheus Holdings, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track LNTH in your portfolio →
Lantheus Holdings, Inc. financial history by metric
Compare Lantheus Holdings, Inc. with peers
About Lantheus Holdings, Inc.
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide. The company offers DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. It also provides Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; PYLARIFY AI, an medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer; and flurpiridaz used to assess blood flow to the heart. In addition, it develops PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy to patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent for Tau tangles in Alzheimer's disease; LNTH-2401, a novel radiodiagnostic targeting the gastrin-releasing peptide receptor; LNTH-2402; LNTH-2403; LNTH-2404; LNTH-250; LNTH-2515; and LNTH-1363S, an fibroblast activation protein, alpha, copper-64 labeled PET imaging agent. It has collaboration agreements with GE Healthcare; Curium Pharma; POINT; Regeneron; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.
Lantheus Holdings, Inc. — frequently asked questions
What is Lantheus Holdings, Inc.'s revenue?
Lantheus Holdings, Inc. (LNTH) reported revenue of $1.54B for fiscal year 2025, up 0.5% from the prior year, according to its SEC filings.
Is Lantheus Holdings, Inc. profitable?
Yes. LNTH earned net income of $233.56M in fiscal 2025, a net margin of 15.2%.
What is LNTH's P/E ratio?
Lantheus Holdings, Inc. trades at a price-to-earnings ratio of about 24.0 based on the latest data in our nightly-refreshed cache.
How fast is Lantheus Holdings, Inc. growing?
LNTH's revenue grew at roughly 35.3% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does Lantheus Holdings, Inc. have?
As of fiscal year 2025, LNTH carried roughly $0 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Lantheus Holdings, Inc.'s gross margin?
LNTH's gross margin was 61.1% in fiscal 2025 — gross profit of $941.95M on revenue of $1.54B.
What is Lantheus Holdings, Inc.'s market cap?
Lantheus Holdings, Inc. (LNTH) has a market capitalization of about $6.55B, based on the latest data in our nightly-refreshed cache.
When does Lantheus Holdings, Inc.'s fiscal year end?
LNTH's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
What growth is priced into LNTH stock?
At today's market cap of $6.55B, Lantheus Holdings, Inc. is priced for free-cash-flow growth of about 6.6% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $354.05M from the FY ending 2025-12-31). For comparison, free cash flow actually grew 84.9%/yr over the last five fiscal years and revenue 35.3%/yr, computed from its SEC filings.
Where does this data come from?
All figures are computed from Lantheus Holdings, Inc.'s official SEC filings (10-K and 10-Q), covering 13 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.